ERBB2 and neoplasm: Based solely on the information submitted in the eCRFs, nine patients did not meet the inclusion criteria (three patients for not having received ≥2 prior anti-HER2–based regimens and six patients for not meeting the inclusion criterion of ‘documented HER2-positive tumor status by a validated method’).